Lead Sponsor

Amgen

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Diagnosis of diabetes mellitus with Hemoglobin A1c \<8.5%
•IGF 1 in serum \> 106 ng/mL
•Women of child-bearing potential must have negative pregnancy test and be willing and able to use two different methods of contraception, one of which must be oral contraceptive or depot formulation. Males must be surgically sterile or agree to use barrier contraception
•Clinically significant DME of less than 12 months duration
•Non-proliferative diabetic retinopathy of moderate severity
•Best corrected electronic ETDRS letter score \< 78 and \> 24

•Unstable-uncontrolled diabetes as demonstrated by a change in diabetes medication greater than 15% in the previous 60 days.
•Significant renal disease, myocardial infarction, stroke, transient ischemic attack, acute congestive heart failure
•Blood pressure \> 180/110
•Anti-vascular endothelial growth factor (VEGF) treatment within two months prior to enrollment
•History of pan retinal photocoagulation within four months prior to enrollment
•History of ocular surgery within four months prior to enrollment
•History of systemic treatment with corticosteroids within 3 months prior to enrollment

Related studies

NCT07425522 · Diabetic Macular Edema

NCT07308639 · Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)

NCT07449936 · Diabetic Macular Edema, DME, and more

NCT07362927 · Diabetic Macular Edema (DME)

NCT07449923 · Diabetic Macular Edema, DME, and more

A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)